Clinical

Dataset Information

0

TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer


ABSTRACT: Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2646936 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2641267 | ecrin-mdr-crc
| 2628236 | ecrin-mdr-crc
| 2632430 | ecrin-mdr-crc
| 2634299 | ecrin-mdr-crc
| 2615622 | ecrin-mdr-crc
| 2636928 | ecrin-mdr-crc
| 2637963 | ecrin-mdr-crc
| 2645202 | ecrin-mdr-crc
| 2637697 | ecrin-mdr-crc
| 2637698 | ecrin-mdr-crc